Managing side effects of menin inhibitors in clinical practice

The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What side effects are typically observed with menin inhibitor-based regimens, and how do you approach managing them in clinical practice?

Roboz provides an overview of the key toxicities associated with menin inhibitor regimens in the treatment of NPM1-mutated (NPM1m) and KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML), including differentiation syndrome, QT prolongation, and drug–drug interactions. She highlights the importance of recognizing these side effects as menin inhibitors move into routine clinical practice and shares how she approaches managing them.

This educational resource is independently supported by Kura Oncology. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.